SERA PROGNOSTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SERA PROGNOSTICS, INC. (SERA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 11.93 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 12.25M shares, a 8.88% increase year-over-year.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 11.25M shares, a 4.66% decline year-over-year.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 11.80M shares, a 1.68% decline year-over-year.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 12.00M shares, a 11.04% increase year-over-year.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.64M shares, a 2.41% increase from fiscal 2024.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.39M shares, a 18.31% decline from fiscal 2023.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.72M shares, a 13.53% increase from fiscal 2022.
- SERA PROGNOSTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 11.20M shares, a 23.46% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.93M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 12.25M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 10.64M shares 10-K · filed 2026-03-18 | |||
| 2025-09-30 | 10.76M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 11.32M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 11.25M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 10.39M shares 10-K · filed 2026-03-18 | |||
| 2024-09-30 | 10.81M shares 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 11.11M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 11.80M shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 12.72M shares 10-K · filed 2025-03-19 | |||
| 2023-09-30 | 10.76M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 11.08M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 12.00M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 11.20M shares 10-K · filed 2024-03-20 | |||
| 2022-09-30 | 11.31M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 11.53M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 10.81M shares 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 9.08M shares 10-K · filed 2023-03-22 | |||
| 2021-09-30 | 8.81M shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 32.11M shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 28.28M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 22.42M shares 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 22.68M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 22.62M shares 10-Q · filed 2021-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |